Sanofi, eyeing impurity concerns, pulls hypertension meds in Korea and the UK. Could the next big ‘sartan’ recall be on the horizon?news2021-08-10T13:25:00+00:00August 10th, 2021|Fierce Pharma|
Sanofi, eyeing impurity concerns, pulls hypertension meds in Korea and the U.K. Could the next big ‘sartan’ recall be on the horizon?news2021-08-10T13:25:00+00:00August 10th, 2021|Fierce Pharma|
Moderna lays plans for new Canadian mRNA vaccine manufacturing site—and more could be on the waynews2021-08-10T13:09:14+00:00August 10th, 2021|Fierce Pharma|
Viatris shows no signs of growing pains in its ‘trough year,’ but one analyst has longer-term worriesnews2021-08-10T11:06:48+00:00August 10th, 2021|Fierce Pharma|
Regeneron scraps sustained-release Eylea alliance with Ocularnews2021-08-10T09:51:46+00:00August 10th, 2021|Fierce Pharma|
Oyster Point sells China rights to nasal sprays for eye diseasenews2021-08-10T09:47:27+00:00August 10th, 2021|Fierce Pharma|
Eyevensys bags $12M to test non-viral gene therapy delivery technews2021-08-10T09:44:14+00:00August 10th, 2021|Fierce Pharma|
J&J’s Ponvory may be late to the multiple sclerosis market, but doctors still see potential: studynews2021-08-09T20:20:04+00:00August 9th, 2021|Fierce Pharma|
Ginkgo and Aldevron tout mRNA manufacturing ‘breakthrough’—and the perks could stretch well beyond COVID-19, exec saysnews2021-08-09T20:05:29+00:00August 9th, 2021|Fierce Pharma|
Biohaven’s Nurtec ODT outmuscles AbbVie’s Ubrelvy in gaining new migraine patients following key FDA nodnews2021-08-09T16:01:48+00:00August 9th, 2021|Fierce Pharma|
